Alnylam Pharmaceuticals | ALNY - Ebit



Alnylam Pharmaceuticals reported $4.89M in EBIT for its fiscal quarter ending in June of 2025.


Ebit Change Date
Acadia Pharmaceuticals USD 32.37M 13.08M Jun/2025
Agios Pharmaceuticals USD -127056000 20.43M Jun/2025
Alnylam Pharmaceuticals USD 4.89M 13.19M Jun/2025
Amgen USD 2.26B 1.34B Jun/2025
Arrowhead Research USD -165550000 546.75M Jun/2025
BioMarin Pharmaceutical USD 276.89M 52.99M Jun/2025
Incyte USD 310.82M 27.18M Jun/2025
Ionis Pharmaceuticals USD 144.78M 290.78M Jun/2025
Moderna USD -817000000 146M Jun/2025
Neurocrine Biosciences USD 145.6M 121.9M Jun/2025
Novartis USD 4.82B 39M Jun/2025
PTC Therapeutics USD -34858000 1.01B Jun/2025
Regeneron Pharmaceuticals USD 1.52B 608.6M Jun/2025
Sanofi EUR 1.51B 704.8M Jun/2025
Sarepta Therapeutics USD 115.58M 415.96M Jun/2025
Takeda JPY 257.79B 387.52B Jun/2025
Tectonic Therapeutic USD -22332000 8.34M Jun/2025
Ultragenyx Pharmaceutical USD -193567000 50.63M Jun/2025
Vertex Pharmaceuticals USD 1.15B 420.8M Jun/2025
Xencor USD -22832000 16.77M Jun/2025